Loading…
China Resources-affiliated plasma products maker producing albumin and immunoglobulin from donated human plasma.
China Resources-affiliated plasma products maker producing albumin and immunoglobulin from donated human plasma.
Raw plasma collected at licensed donation stations is the scarce input, so the number of stations and the plasma each collects limit output more than sales do; products then go mostly to hospitals through distributors. China Resources, a state-owned group, is the controlling shareholder.
In one line: A Chinese CSL Behring/Grifols.
Moat: narrow (regulatory licence, scale). Plasma-collection licences and blood-product manufacturing approvals are tightly state-regulated and slow to obtain.
Headquarters: Guangzhou, China · Employees: 1,947
Size China Resources Boya Bio-pharmaceutical (300294.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.06B, the 2185th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥14.25 on 6 Nov 2026.
Performance Over six months the shares fell 18.5%, against -15.3% for the median peer and -16.4% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue fell 27.1% over the last twelve months (peer median +9.7%); the operating margin is -18.7% (peer median 8.1%).
Valuation It trades at 23.8× forward earnings against a peer median of 21.0× (6th most expensive of 14).
Capital Return on invested capital runs 8.9 points below its cost of capital (6.3% WACC).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.43B | CN¥2.05B | CN¥1.73B | CN¥2.64B | CN¥2.75B |
| Revenue growth | — | +19% | -35% | -4% | — |
| Gross profit | CN¥649M | CN¥937M | CN¥1.06B | CN¥1.33B | CN¥1.44B |
| EBITDA | n/a | CN¥434M | CN¥539M | CN¥642M | CN¥619M |
| Net income | -CN¥168M | CN¥113M | CN¥397M | CN¥237M | CN¥432M |
| Free cash flow | -CN¥445M | -CN¥419M | CN¥193M | CN¥653M | CN¥533M |
| Capital expenditure | CN¥472M | CN¥535M | CN¥198M | CN¥87.5M | CN¥138M |
| Total debt | CN¥167M | CN¥333M | CN¥220M | CN¥74.2M | CN¥68.4M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| China Resources Boya Bio-pharmaceutical 300294.SZ | $1.06B | -18% | -27% | -19% | 23.8× | n/a |
| Shanghai RAAS Blood Products 002252.SZ | $4.89B | -11% | -22% | 17% | 13.7× | n/a |
| CSL CSL.AX | $67.2B | +105% | -2% | 26% | 22.4× | 7.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300294.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.8% | -6.0% | 10th highest of 21 |
| 6-month return | -18.5% | -15.3% | 9th lowest of 20 |
| Distance from 52-week high | -44.4% | -33.7% | 7th lowest of 21 |
| Revenue growth (TTM) | -27.1% | +9.7% | 3rd lowest of 19 |
| Operating margin | -18.7% | 8.1% | 5th lowest of 19 |
| Forward P/E | 23.8× | 21.0× | 6th most expensive of 14 |
| ROIC minus cost of capital | -8.9 pp | -0.3 pp | 4th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| China Resources Boya Bio-pharmaceutical 300294.SZ | China | $1.06B | -18% | -27% | -19% | 23.8× | n/a | n/a |
| Renhe Pharmacy 000650.SZ | China | $1.06B | -10% | -7% | 14% | 17.7× | -9.4% | -7.0% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $1.07B | -47% | -55% | -457% | n/a | n/a | n/a |
| Basilea Pharmaceutica BSLN.SW | Switzerland | $1.07B | +27% | +5% | 24% | 12.4× | -5.7% | +12.7% |
| Viyash Scientific VIYASH.NS | India | $1.07B | +3% | +96% | 13% | 30.3× | 38.6% | +20.4% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.07B | -38% | +117% | -89% | n/a | n/a | n/a |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $1.07B | -15% | +8% | 7% | n/a | 34.1% | -6.0% |
| Jiangsu Kanion Pharmaceutical 600557.SS | China | $1.05B | -6% | +8% | 7% | 21.0× | 3.4% | +1.8% |
| Zhejiang Tianyu Pharmaceutical 300702.SZ | China | $1.08B | -2% | +27% | 4% | 22.7× | 5.0% | +3.5% |
| Sunflower Pharmaceutical 002737.SZ | China | $1.04B | -13% | +31% | -7% | 4.8× | -6.4% | -7.7% |
| BeBetter Med 688759.SS | China | $1.08B | -49% | n/a | n/a | n/a | n/a | n/a |
| Chengdu Easton Biopharmaceuticals 688513.SS | China | $1.09B | -35% | -2% | 13% | 26.5× | 5.5% | +7.7% |
| Towa Pharmaceutical 4553.T | Japan | $1.03B | -16% | +7% | 9% | 7.0× | 1.5% | +12.1% |
| SAWAI 4887.T | Japan | $1.03B | -22% | +11% | 9% | 10.9× | n/a | n/a |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chongqing Taiji Industry (Group) 600129.SS | China | $1.09B | -15% | -4% | 2% | 26.5× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Jiangxi Fushine Pharmaceutical 300497.SZ | China | $1.10B | -29% | +103% | 24% | 10.6× | 8.6% | -4.5% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $1.10B | -51% | +19% | 9% | 49.2× | 13.9% | +4.9% |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| Bio-Thera Solutions 688177.SS | China | $1.10B | -14% | +24% | -44% | n/a | n/a | n/a |